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OBJECTIVE — Quick-release bromocriptine (bromocriptine-QR), a D2 dopamine receptor
agonist, is indicated as a treatment for type 2 diabetes. The Cycloset Safety Trial, a 52-week,
randomized, double-blind, multicenter trial, evaluated the overall safety and cardiovascular
safety of this novel therapy for type 2 diabetes.
RESEARCHDESIGNANDMETHODS — Atotalof3,095patientswithtype2diabetes
were randomized 2:1 to bromocriptine-QR or placebo in conjunction with the patient’s usual
diabetes therapy (diet controlled only or up to two antidiabetes medications, including insulin).
The all-cause–safety end point was the occurrence of any serious adverse event (SAE), with a
hazard ratio (HR) noninferiority margin of 1.5. In a prespeciﬁed analysis, the frequency of
cardiovascular disease (CVD) events deﬁned as a composite of myocardial infarction, stroke,
coronary revascularization, and hospitalization for angina or congestive heart failure was eval-
uated using modiﬁed intent-to-treat analysis (clinicaltrials.gov, NCT00377676).
RESULTS — In the bromocriptine-QR group, 176 (8.6%) people reported SAEs compared
with98(9.6%)intheplacebogroup(HR1.02[96%one-sidedCI1.27]).Fewerpeoplereported
a CVD end point in the bromocriptine-QR group versus the placebo group (37 [1.8%] vs. 32
[3.2%], respecively) (HR 0.60 [95% two-sided CI 0.35–0.96]). Nausea was the most commonly
reported adverse event in the bromocriptine-QR group.
CONCLUSIONS — The frequency of SAEs was comparable between the treatment arms.
Compared with patients in the placebo arm, fewer patients taking bromocriptine-QR experi-
enced a cardiovascular end point.
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T
ype 2 diabetes is a growing global
pandemic that is estimated to afﬂict
approximately 350 million people
by the year 2030 (1,2). This growing
threat to human health requires medical
interventions to lessen the morbidity as-
sociated with type 2 diabetes. Results
from several recent clinical trials have
raised concerns about the cardiovascular
safety of current therapies and therapeu-
tic strategies (3–10). Therefore, the U.S.
Food and Drug Administration has estab-
lished cardiovascular safety standards
that must be met for type 2 diabetes ther-
apies prior to their marketing approval.
The Cycloset Safety Trial was designed to
assess the overall safety and speciﬁcally
address cardiovascular safety for a novel
treatment for type 2 diabetes, quick-
release bromocriptine (bromocriptine-
QR) (11).
Bromocriptine is a dopamine D2 re-
ceptor agonist, and bromocriptine-QR
was designed to provide a short duration
pulse of this dopamine agonist to centers
in the brain (12,13) that regulate periph-
eral fuel metabolism (14). Bromocrip-
tine-QR is administered in the morning,
within2ho fwaking, to effectuate an in-
crease in central dopaminergic tone at the
time of day it normally peaks in healthy
individuals (15). This circadian peak in
central dopaminergic tone has been
linkedtopreservationand/orinductionof
normal insulin sensitivity and glucose
metabolism in several preclinical studies
(14). Although bromocriptine-QR had
demonstrated improvements in various
metabolic parameters in patients with
type 2 diabetes as well as improvements
in many surrogate markers of cardiovas-
culardisease,(16,17)datafromthesepre-
vious clinical studies were insufﬁciently
powered to adequately assess cardiovas-
cularsafety.Thisarticlereportstheresults
of a 1-year, double-blind, placebo-
controlled, randomized clinical trial
where the overall safety and speciﬁcally
cardiovascular safety of bromocrip-
tine-QR was the primary outcome.
RESEARCH DESIGN AND
METHODS— The Cycloset Safety
Trial study protocol has been previously
published in abbreviated form (11). Pa-
tients were recruited from 74 centers
acrosstheU.S.andPuertoRico,including
19 Veterans Affairs (VA) hospitals. Eligi-
ble patients had type 2 diabetes, as de-
ﬁned by the 2004 American Diabetes
Association guidelines (18), were be-
tween the ages of 30 and 80 years, had a
BMI of 43 kg/m
2, and an A1C level
10.0%. Exclusion criteria were current
chronic (greater than 10 days) use of pre-
scription sympathomimetic drugs, ergot
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medications, clinically signiﬁcant comor-
bid conditions such as uncontrolled
hypertension, New York Heart Classiﬁca-
tion (NYHC) III-IV congestive heart fail-
ure, renal failure, or cancer (other than
nonmelanoma skin or nonmetastatic
prostate cancer) within the past 5 years.
Patients with NYHC I-II congestive heart
failure were allowed in the trial as were
those with signiﬁcant cardiovascular dis-
ease, including a cardiovascular event
prior to 6 months before screening.
Patients were required to be on a sta-
ble antidiabetes regimen consisting of ei-
ther diet, oral hypoglycemic agents (no
more than two), or insulin (alone or with
no more than one oral hypoglycemic
agent) for at least 30 days prior to ran-
domization after a two-week lead-in pe-
riod. Patients were randomized in a 2:1
ratio to their usual antidiabetes regimen
plus bromocriptine-QR or placebo taken
with their morning meal. During the ﬁrst
6 weeks of the study, the daily dose of the
study drug was titrated up by one tablet
(0.8 mg) per day on a weekly basis until a
maximaldoseofuptosixtablets(4.8mg)
per day was achieved or until the patient
could not tolerate a higher dose.
Patients were required to continue
their usual antidiabetes regimen during
the ﬁrst 3 months of the study but were
allowed to alter the dosages of these med-
icationstooptimizebloodglucosecontrol
as deemed appropriate by the site inves-
tigator(19).After3months,alterationsto
antidiabetes medications (elimination or
addition of an agent) were allowed when
necessary, but if a medication was added
the ﬁnal regimen was limited to no more
than two oral antidiabetes agents, or no
morethanoneantidiabetesagentiftaking
insulin.
During the ﬁrst 6 weeks of the study,
patients were called weekly, had ofﬁce
visits at weeks 3 and 6, and then visits
every 3 months until the study end (week
52) or early termination. Patients were
contacted 30 days after stopping a study
drugtorecordanyadverseeventsthatoc-
curredaftercessation.Physicalexamsand
laboratory assessments (blood chemis-
tries, hematology, and urine analyses)
were obtained at baseline, week 24, and




board for non-VA centers.
Outcome measures
ThereweretwomainobjectivesoftheCy-
closet Safety Trial: 1) assessment of over-
all safety of bromocriptine-QR by
measuring the frequency of serious ad-
verse events (SAEs) among patients tak-
ing bromocriptine-QR and placebo, and
2)cardiovascularsafetyassessedbydeter-
mining the frequency of major cardiovas-
cular events, deﬁned as a composite of
ﬁrst myocardial infarction, stroke, coro-
nary revascularization, or hospitalization
for angina or congestive heart failure that
occurred after randomization. An inde-
pendent adverse event adjudication
committee (AEAC) consisting of two car-
diologists and an endocrinologist,
blinded to treatment assignment and
Medical Dictionary for Regulatory Activi-
ties (MedDRA) coding of events by the
study team, made the ﬁnal SAE system
organ class (SOC) classiﬁcations and as-
signment of an SAE as a cardiovascular
end point.
Additional safety measures included
laboratory measures (blood chemistries,
hematology, and urine analyses) at weeks
0, 24, and 52 of the study and evaluation
of electrocardiograms (ECGs) at weeks 0,
24, 52 or early termination.
Statistical analysis
An analysis of noninferiority tested the
hypothesis that usual antidiabetes ther-
apy (UADT) plus bromocriptine-QR is
not inferior to that of UADT plus placebo
in terms of the occurrence of all-cause
SAEs using a one-sided 0.05 level. In
order to test the primary hypothesis at a
one-sided 0.05 and with a power of
one   0.90 when the noninferiority
marginis1.5,thetotalnumberofpatients
with all-cause SAEs needed during the
study was calculated to be 235. All ran-
domized patients that took at least one
dose of study drug were included in the
all-cause SAE analysis. SAEs that oc-
curred on a study drug or within 30 days
of stopping a study drug were considered
as treatment emergent events. Statistical
testing between the two groups was con-
ducted using the two-sided 91.9% CI for
the rate ratio of all-cause SAEs because
thisprovidesthesameconﬁdencebound-
aries as a one-sided 96% CI. The ﬁnal
analysistakesintoaccountoneinterimtest-
ing. The CI was estimated by the corre-
spondingestimateforthehazardratio(HR)
with Cox regression analysis with consider-
ation for possible center interaction.
The analysis of the composite cardio-
vascular endpoint used the modiﬁed in-
tent-to-treat population of patients
receivingatleastonedoseofastudydrug.
Superiority or noninferiority between
bromocriptine-QR and placebo for the
composite CVD end point was deﬁned as
the upper bound of the two-sided 95%
conﬁdence limit being 0 and 1.5, re-
spectively. Assuming a CVD composite
event rate of 3.4%, this sample size pro-
vided a power of 75% to demonstrate
CVD noninferiority. Upon conﬁrming
noninferiority, a sequential superiority
analysis of CVD end point based on the
Cox proportional-hazards regression
with two-sided P values was then calcu-
lated. No interim analysis was conducted
on the CVD end point. Analysis of the
CVD end point was conducted adjusting
for baseline covariates including history
of stroke and cardiovascular revascular-
ization and center.
Changes in laboratory measures were
assessed using the Wilcoxon rank sum
testexceptforA1C,whichwasbasedona
general linear model with baseline and
treatment as ﬁxed effects. The signiﬁcant
level was set at P  0.05.
All statistical analyses were con-
ducted by Everest Inc. (Toronto, Canada)
using SAS software version 8.2 (Cary,
NC).
RESULTS— A total of 4,074 patients
were screened and 879 patients were ex-
cluded for not meeting eligibility criteria,
withdrawal of consent, or other reasons.
Ofthe3,070patientsthatreceivedastudy
drug, 47% stopped treatment on bro-
mocriptine-QR and 32% stopped treat-
ment on placebo prior to the ﬁnal study
visit.Theontreatmentexposuretimewas
1,643 person-years and 914 person-years
for bromocriptine-QR and placebo, re-
spectively, which represents 77 and 86%
oftheexpectedperson-time,respectively.
Additionally, 82% of the study patients
had ﬁnal assessments, which accounts for
91% of the expected person time for this
trial (2,906 of 3,193 possible total per-
son-years) (Appendix IV, Figure A, avail-




The study included a diverse population
of patients with type 2 diabetes (Table 1)
with the majority of patients receiving
cardioprotectivemedications.Onaverage
for the study population, the baseline
A1C, lipid, and blood pressure values in-
dicatedreasonablygoodcontrolofhyper-
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tension, respectively; however, the pres-
enceofcardiovasculardiseasewasstillprev-
alent. Overall, there were no differences in
baseline characteristics between the groups
that would not be expected by chance.
Clinical outcomes
SAEs. There were 374 SAEs among 274
people. All SAEs were grouped by SOC
(Table 2). SAEs occurred among 9.6% of
placebo-treated patients versus 8.6% of
bromocriptine-QR–treated patients.
Aside from the cardiac SOC class, the fre-
quency of all remaining SAEs grouped by
SOC was similar between bromocrip-
tine-QR and placebo. It should be noted
that the cardiac SOC includes a much
broader deﬁnition comprising thirty-
seven preferred terms (i.e., arrhythmia,
chest pain, syncope) as opposed to the
prespeciﬁed cardiovascular end point.
Intheanalysisoftimetoﬁrstall-cause
SAE, the and upper bound of the one-
sided conﬁdence limit support noninferi-
ority between bromocriptine-QR and
placebo, (HR 1.02 [96% one-sided CI
1.27]). The treatment effect did not
change appreciably with the addition of
the baseline covariates of age, duration of
diabetes, insulin usage, sex and race. The
center by treatment interaction term was
also nonsigniﬁcant.
CVD. The composite CVD end point
occurred in 37 bromocriptine-QR–
treated (1.8%) and 32 placebo-treated
(3.2%) patients resulting in a 40% CVD
relative risk reduction (HR 0.60 [95%
two-sided CI 0.37–0.96]; Table 2). The
observed CVD risk reduction did not
change appreciably with the addition of
the baseline covariates of age, baseline
A1C level, sex, race, and prior history of
stroke or prior history of coronary
revascularization.
Figure 1 shows the Kaplan-Meier es-
timates of the proportion of patients by
treatment that experienced an event
within the composite end point and dem-
onstrates a clear separation in the curves
that begins after 3 months of treatment.
Deaths. The frequency of deaths that
occurred while on a study drug or within
30daysofstoppingastudydrugwassim-
ilarbetweenthetreatmentgroups(0.19%
bromocriptine-QR, 0.20% placebo). Five
patients randomized to bromocrip-
tine-QR and one randomized to placebo
died in excess of 30 days after stopping
the study drug.
Overall adverse events summary
Adverse events (AEs) occurred in 89% of
bromocriptine-QR–treated and 83% of
placebo-treated patients. AEs were not
commonly reported as severe in either
treatment group (17% events reported as
severe on bromocriptine-QR compared
with 14% on placebo). More patients dis-
continued bromocriptine-QR than pla-
cebo due to an adverse event (24% vs.
11%, respectively). The most commonly
reported adverse event among patients
whodiscontinuedbromocriptine-QRwas
nausea (7.6% bromocriptine-QR vs. 1%
placebo). The only AEs that occurred at a
frequency rate of at least 5% and were
numerically greater in the bromocrip-
tine-QR arm were nausea, vomiting, diz-
ziness, headache, and diarrhea. Nausea
was the most common adverse event




Mean age (years) 59.5  10.2 60.2  9.97
Duration of diabetes diagnosis (years) 7.9  7.42 8.0  7.41
BMI (kg/m
2) 32.4  5.08 32.3  5.07
Waist circumference (inches) 41.8  5.11 42.0  5.52
Male sex 1,141 (56) 598 (59)
Caucasian 1,381 (67) 698 (69)
African American 348 (17) 168 (16.5)
Hispanic 277 (13.5) 131 (13)
Asian 4 (1.1) 3 (1.6)
Health risks
Hypertension 1,548 (75) 767 (75.5)
Angina pectoris 214 (10) 101 (10)
Myocardial infarction 186 (9.1) 106 (10)
Revascularization surgery 204 (10) 128 (13)
Stroke 87 (4.2) 65 (6.3)
Hypercholesterolemia* 1,575 (77) 767 (75.5)
Hypertriglyceridemia 853 (41.5) 422 (41.5)
Current smoker 306 (15) 133 (13)
Former smoker 802 (39) 419 (41)
Diabetes treatment
Diet only 257 (12) 114 (11)
One oral hypoglycemic agent 806 (39) 403 (40)
Two oral hypoglycemic agents 686 (33) 323 (32)
Oral agent plus insulin 171 (8) 98 (10)
Insulin only 133 (6) 78 (8)
Not reported 1 0
Antidiabetes medications
Insulin 309 (15) 176 (17)
Metformin 1,209 (59) 581 (57)
Rosiglitazone 233 (11) 111 (11)
Pioglitazone 161 (8) 83 (8)
Sulfonylurea/glinide 759 (37) 392 (39)
Cardio-protective medications
ACE inhibitors 994 (48) 477 (47)
Angiotensin II receptor inhibitors 271 (13) 135 (13)
Beta blockers 452 (22) 247 (24)
Diuretics, thiazide 445 (22) 233 (23)
Sulfamides, loop diuretics 166 (8) 89 (9)
Other diuretic† 75 (4) 49 (5)
Calcium channel blockers‡ 362 (18) 202 (20)
Hmg CoA reductase inhibitor 1,165 (57) 594 (58)
Fibrate 157 (8) 78 (8)
Platelet aggregation inhibitors 943 (46) 500 (49)
Data are means  SD or n (%). *Based on history as assessed by study site investigator. †Other diuretics
include aldosterone inhibitors, low ceiling diuretics. ‡Calcium channel blockers include dihydropryidine,
pheny-alkylamine, benozothiazepine.
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reported as serious. The majority of the
commonly occurring adverse events at-
tributed to bromocriptine-QR occurred
during the initial titration phase were
dose related and transient in nature
(mean duration of 14 days). After the
initial titration phase, commonly occur-
ring adverse events were reported at a fre-
quency similar to that observed in the
placebo treated arm.
Other AEs
Somnolence (4.3 bromocriptine-QR vs.
1.3%placebo)andhypoesthesia(1.4bro-
mocriptine-QR vs. 1.1% placebo) were
the only AEs within the nervous system
organ class that were reported at a rate of
5% and 1% and that occurred at a
numerically greater frequency among
bromocriptine-QR-treated patients. Ad-
ditionally, 15 (0.7%) of patients on bro-
mocriptine-QRand14(1.4%)onplacebo
reported depression or depressed mood,
and 13 (0.6%) patients on bromocrip-
tine-QR and 8 (0.8%) on placebo re-
ported anxiety. Hypoglycemic AEs
occurred infrequently, with 6.9% bro-
mocriptine-QR patients reporting an
event versus 5.3% in the placebo-
treated arm.
Laboratory measures, vital signs,
and electrocardiograms
There were no signiﬁcant differences be-
tweenthetreatmentarmsinchangesfrom
baseline in hematology or chemistry lab-
oratory values. There were minimal
changes from baseline in lipid measures
and blood pressure in both groups (on-
line appendix IV, Table B). Compared
with those on placebo, heart rate among
patients randomized to bromocrip-
tine-QR decreased 1 bpm from a base-
line study population mean heart rate of
68 bpm at week 52 (P  0.02). The cor-
rected QT interval decreased, albeit non-
signiﬁcantly, from baseline to week 52
among bromocriptine-QR–treated pa-
tientsby3.2ms(baselineaverage418ms)
and by 1.9 ms for the placebo arm (base-
lineaverage420ms).Therewasnodiffer-
ence in the mean change in body weight
from baseline to week 52 for either bro-
mocriptine-QR (0.2 kg) or placebo
(0.1 kg).
CONCLUSIONS — The present study
istheﬁrsttoassess,asaprimaryobjective
and end point, the overall and cardiovas-
cular safety of a new oral antidiabetes
therapy in a large population of patients
with type 2 diabetes. The ﬁndings from
this trial indicate that morning bro-
mocriptine-QR therapy is noninferior to
placebo for overall safety. The overall fre-
quency of all-cause SAEs and the propor-
tionofSAEsobservedineachSOCamong
patients taking bromocriptine-QR was
noninferior to the frequency among pa-
tients in the placebo arm. Furthermore,
thefrequencyofthecompositecardiovas-
cular end point was statistically signiﬁ-
cantly reduced in the bromocriptine-QR
group compared with the placebo group.
The Kaplan-Meier estimates indicate
that among 1,000 patients allocated to
bromocriptine-QR, 13 ﬁrst myocardial
infarctions, strokes, coronary revascular-
izations, hospitalizations for congestive
heartfailure,orhospitalizationsforunsta-
ble angina would be avoided over 1 year.
Simply stated, 79 patients would need to
be treated for 1 year to avoid one ﬁrst
important CVD event. It should be ap-
preciated that the reduction in CVD
events occurred among a study popula-
tion where the majority of the patients
were receiving appropriate cardiopro-
tective medications and where blood
pressure, glucose and lipids on average
were optimally controlled. Further-
more, these results were demonstrated
among patients with an average dura-
tion of type 2 diabetes of 8 years and in
which a third had preexisting cardio-
vascular disease.
Bromocriptine-QR was developed to
provide a discrete and brief daily interval
of circulating bromocriptine at a particu-




Cardiac** 51 (2.5) 37 (3.6)
Infections and infestations 27 (1.3) 13 (1.3)
Nervous system disorders 26 (1.3) 14 (1.4)
General disorders 14 (0.7) 9 (0.9)
Gastrointestinal disorders 13 (0.6) 9 (0.9)
Vascular disorders 10 (0.5) 8 (0.8)
Respiratory, thoracic and mediastinal 13 (0.6) 3 (0.3)
Injury, poisoning, and procedural complications 12 (0.6) 3 (0.3)
Musculoskeletal and connective tissue 11 (0.5) 4 (0.4)
Neoplasm benign, malignant, and unspeciﬁed 8 (0.4) 2 (0.2)
Endocrine 5 (0.2) 4 (0.4)
Hypoglycemia† 4 (0.2) 4 (0.4)
Metabolism and nutrition disorders 7 (0.3) 2 (0.2)
Renal and urinary disorders 6 (0.3) 3 (0.3)
Hepatobiliary disorders 4 (0.2) 1 (0.1)
Psychiatric disorders 4 (0.2) 1 (0.1)
Reproductive system and breast disorders 4 (0.2) 0
Eye disorders 0 2 (0.2)
Any SAE 176 (8.6) 98 (9.6)
Hazard ratio and 96% one-sided conﬁdence limit 1.02 (—, 1.27)
Prespeciﬁed adjudicated composite cardiovascular endpoint
Time to ﬁrst composite CVD event 37 (1.8%) 32 (3.1%)
Hazard ratio and 95% conﬁdence limit 0.60 (0.37–0.96)
Composite CVD end point by each component‡
Myocardial infarction 7 (0.3) 9 (0.9)
Stroke 5 (0.2) 6 (0.6)
Hospitalization for unstable angina 9 (0.4) 9 (0.9)
Hospitalization for congestive heart failure 9 (0.4) 6 (0.4)
Coronary revascularization 11 (0.5) 8 (0.8)
Data are n (%). *SOC as determined by MedDRA coding of preferred term provided by study investigator.
Patients may appear in more than one system organ category if they experienced multiple AEs belonging to
different SOCs. All SAEs were adjudicated by an independent AEAC. **The cardiac SOC includes 37
different preferred terms such as arrhythmia, myocardial infarction, chest pain, and coronary artery disease;
however the composite cardiovascular end point comprised events that met the prespeciﬁed end point
criteria set forth by an independent AEAC that was blinded to treatment assignment. †Hypoglycemia is a
subcategory of the endocrine SOC. ‡Patients may appear in more than one component of the composite
cardiovascular end point if they experienced multiple cardiovascular AEs.
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provide a timed pulse of dopamine activ-
ity centrally. This formulation/treatment
feature differentiates bromocriptine-QR
bioavailability and dosing from the mul-
tiple-times per day and higher overall
dosing of traditional formulations of bro-
mocriptine for other indications such as
Parkinson’s disease or acromegaly, which
may deliver higher circulating drug levels
throughout the day and as a conse-
quence prolonged dopamine stimulation
centrally.
The mechanism by which such timed
bromocriptine-QRmayreducecardiovas-
cular outcomes is not clear. In this trial,
treatmentwithbromocriptine-QRwasas-
sociatedwithreductionsinfastingtriglyc-
eride levels, blood pressure, and heart
rate but not to the extent one would ex-
pect to explain the observed CVD risk re-
duction. Improvements in a host of CVD
risk factors in addition to glycemic con-
trol are likely necessary to truly attenuate
the excessive risk of CVD events experi-
enced by patients with type 2 diabetes
(20). The peripheral cardiometabolic ef-
fects of bromocriptine-QR on cardiovas-
cular risk may be in part the consequence
of its attenuation of central nervous sys-
tem and hypothalamic functions potenti-
ating sympathetic nervous system over-
activity to the vasculature, visceral
adipose, and liver as well as attenuation
of increased hypothalamic-pituitary-
adrenal axis activity, (14) which are
known to increase CVD risk if overactive
(21,22). Improvements in postprandial
hyperglycemia and hyperlipidemia (16)
have been observed with this treatment
and may have contributed to the CVD
eventreductioninthistrial.Moreover,re-
cent studies in animal models of insulin
resistancehavedemonstratedmarkedim-
provements in both liver inﬂammatory
pathways potentiating vascular damage
and endothelial dysfunction during treat-
ment with a parental formulation of bro-
mocriptine (A.C., unpublished data).
Although increased sympathetic tone
(23), postprandial dysmetabolism (24),
endothelial dysfunction and inﬂamma-
tion (25) are important CVD risk factors
that have been attenuated with bro-
mocriptine therapy in previous clinical
and preclinical studies, the impact of bro-
mocriptine-QR on these measures was
not assessed in this study. Much more
work is required to completely under-
standthecomplexbiochemicalandphys-
iological mechanisms by which timed
bromocriptine-QR produces its potential
cardiovascular effects. A study of longer
duration and sufﬁcient size to provide a
greater number of cardiovascular out-
comes could allay any concerns that the
results in this trial are a chance ﬁnding
while further quantifying the potential
long-term reduction in cardiovascular
events.
Nausea was the chief limiting adverse
event in this trial. For the majority of pa-
tientsexperiencingnausea,thesymptoms
occurred during the initial titration of the
drug and lasted less than 2 weeks. The
gastrointestinal side effects associated
with bromocriptine-QR are dose related
and the “forced” titration scheme (rechal-
lenge with study drug after an AE at a
givendoseandattempttocontinuetoup-
titrate to achieve a maximum tolerated
dose of 4.8 mg) likely contributed to a
higher than expected discontinuation
rate. The incidence rates of hypoglycemia
werelowandsimilarbetweenbromocrip-
tine-QR and placebo groups. Impor-
tantly, the lack of hypoglycemic AEs was
observed even when bromocriptine-QR
was used as add-on therapy to a variety of
antidiabetes agents including insulin.
Figure 1—Kaplan-Meier curve of the occurrence of the prespeciﬁed composite cardiovascular end point among patients randomized to bromocrip-
tine-QR or placebo. The composite cardiovascular end point consisted of the time to ﬁrst myocardial infarction, stroke, coronary revascularization,
hospitalizationforunstableangina,orhospitalizationforcongestiveheartfailurethatoccurredafterrandomization.Allcardiovasculareventswere
independently adjudicated. The hazard ratio of bromocriptine-QR versus placebo for the occurrence of the composite cardiovascular end point was
0.60(95%CI0.37–0.96).TheeffectoftreatmentwasestimatedfromtheunadjustedCoxproportional-hazardmodelthatusedalltheavailabledata.
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tine-QR does not increase insulin levels
and primarily reduces postprandial glu-
cose by way of improving the body’s re-
sponsiveness to insulin (16).
Bromocriptine-QR represents a new
treatment modality for type 2 diabetes. In
patientswithtype2diabetes,theaddition
of bromocriptine-QR to routine standard
ofcaretherapieswasshowntobesafeand
associated with fewer cardiovascular out-
comes. This ﬁrst-in-class therapy may
provideanewapproachtoaddressingthe
comorbidities associated with type 2
diabetes.
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